We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AVEO Pharmaceuticals, Inc. incurred a loss of 42 cents per share in second-quarter 2020, narrower than the Zacks Consensus Estimate of a loss of 51 cents but wider than the year-ago quarter’s loss of 20 cents.
The company’s top line comprises collaboration and licensing revenues plus partnership royalties. Total revenues in the reported quarter were $0.75 million compared with $0.7 million in second-quarter 2019. However, revenues missed the Zacks Consensus Estimate of $1 million.
Shares of the company have lost 25.7% year to date against the industry’s growth of 5.3%.
Operating Expenses
Research & development expenses soared 69.2% year over year to $4.4 million. Meanwhile, general and administrative expenses increased 23.2% year over year to $3.7 million.
Pipeline Updates
In June 2020, the FDA accepted for filing the company’s new drug application (NDA) seeking approval for tivozanib, the next-generation vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), as a treatment for relapsed or refractory RCC. The FDA set an action date of Mar 31, 2021.
The company is preparing for the launch of tivozanib in the United States. It also announced that the FDA has conditionally accepted "Fotivda" as the proprietary brand name for tivozanib in the United States.
AVEO plans to submit an investigational new drug (IND) application to the FDA for AV-380, its first-in-class, potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), for the treatment of cancer cachexia by end of 2020.
In May 2020, AVEO announced that the phase Ib/II DEDUCTIVE study evaluating tivozanib in combination with Imfinzi (durvalumab), AstraZeneca’s human monoclonal antibody directed against programmed death-ligand 1 (PD-L1), in patients with first line metastatic HCC had progressed to the phase II portion of the study.
Cash Position
AVEO had $79.5 million worth of adjusted cash, cash equivalents and marketable securities as of Jun 30, 2020. Management believes that its cash balance along with anticipated partnership payments and royalty revenues from Fotivda sale by EUSA will help fund its planned operations through 2022.
AVEO Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Some better-ranked stocks in the healthcare sector include Emergent Biosolutions Inc. (EBS - Free Report) , Horizon Therapeutics Public Limited Company and Alimera Sciences Inc. (ALIM - Free Report) . While Emergent and Horizon Therapeutics sport a Zacks Rank #1 (Strong Buy), Alimera carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Emergent’s earnings estimates have increased from $3.27 to $5.60 for 2020 and from $3.35 to $6.67 for 2021 over the past 60 days.
Horizon Therapeutics’ earnings estimates have increased from $1.77 to $2.16 for 2020 and from $2.72 to $3.26 for 2021 over the past 60 days.
Alimera’s loss per share estimates have narrowed from $2.33 to $1.31 for 2020 and from 63 cents to 52 cents for 2021 over the past 60 days.
Zacks’ Single Best Pick to Double
From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. From those 5, Zacks Director of Research, SherazMian hand-picks one to have the most explosive upside of all. With users in 180 countries and soaring revenues, it’s set to thrive on remote working long after the pandemic ends. No wonder it recently offered a stunning $600 million stock buy-back plan. The sky’s the limit for this emerging tech giant. And the earlier you get in, the greater your potential gain.
Image: Bigstock
AVEO Pharmaceuticals' (AVEO) Q2 Earnings Surpass Estimates
AVEO Pharmaceuticals, Inc. incurred a loss of 42 cents per share in second-quarter 2020, narrower than the Zacks Consensus Estimate of a loss of 51 cents but wider than the year-ago quarter’s loss of 20 cents.
The company’s top line comprises collaboration and licensing revenues plus partnership royalties. Total revenues in the reported quarter were $0.75 million compared with $0.7 million in second-quarter 2019. However, revenues missed the Zacks Consensus Estimate of $1 million.
Shares of the company have lost 25.7% year to date against the industry’s growth of 5.3%.
Operating Expenses
Research & development expenses soared 69.2% year over year to $4.4 million. Meanwhile, general and administrative expenses increased 23.2% year over year to $3.7 million.
Pipeline Updates
In June 2020, the FDA accepted for filing the company’s new drug application (NDA) seeking approval for tivozanib, the next-generation vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), as a treatment for relapsed or refractory RCC. The FDA set an action date of Mar 31, 2021.
The company is preparing for the launch of tivozanib in the United States. It also announced that the FDA has conditionally accepted "Fotivda" as the proprietary brand name for tivozanib in the United States.
AVEO plans to submit an investigational new drug (IND) application to the FDA for AV-380, its first-in-class, potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), for the treatment of cancer cachexia by end of 2020.
In May 2020, AVEO announced that the phase Ib/II DEDUCTIVE study evaluating tivozanib in combination with Imfinzi (durvalumab), AstraZeneca’s human monoclonal antibody directed against programmed death-ligand 1 (PD-L1), in patients with first line metastatic HCC had progressed to the phase II portion of the study.
Cash Position
AVEO had $79.5 million worth of adjusted cash, cash equivalents and marketable securities as of Jun 30, 2020. Management believes that its cash balance along with anticipated partnership payments and royalty revenues from Fotivda sale by EUSA will help fund its planned operations through 2022.
AVEO Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
AVEO Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | AVEO Pharmaceuticals, Inc. Quote
Zacks Rank & Stocks to Consider
AVEO currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the healthcare sector include Emergent Biosolutions Inc. (EBS - Free Report) , Horizon Therapeutics Public Limited Company and Alimera Sciences Inc. (ALIM - Free Report) . While Emergent and Horizon Therapeutics sport a Zacks Rank #1 (Strong Buy), Alimera carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Emergent’s earnings estimates have increased from $3.27 to $5.60 for 2020 and from $3.35 to $6.67 for 2021 over the past 60 days.
Horizon Therapeutics’ earnings estimates have increased from $1.77 to $2.16 for 2020 and from $2.72 to $3.26 for 2021 over the past 60 days.
Alimera’s loss per share estimates have narrowed from $2.33 to $1.31 for 2020 and from 63 cents to 52 cents for 2021 over the past 60 days.
Zacks’ Single Best Pick to Double
From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. From those 5, Zacks Director of Research, SherazMian hand-picks one to have the most explosive upside of all. With users in 180 countries and soaring revenues, it’s set to thrive on remote working long after the pandemic ends. No wonder it recently offered a stunning $600 million stock buy-back plan. The sky’s the limit for this emerging tech giant. And the earlier you get in, the greater your potential gain.
Click Here, See It Free >>